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Abstract
Introduction: Candidemia raises numerous therapeutic issues for intensive care physicians. Epidemiological data that 
could guide the choice of initial therapy are still required. This analysis sought to compare the characteristics of 
intensive care unit (ICU) patients with candidemia due to non-albicans Candida species with those of ICU patients with 
candidemia due to Candida albicans.
Methods: A prospective, observational, multicenter, French study was conducted from October 2005 to May 2006. 
Patients exhibiting candidemia developed during ICU stay and exclusively due either to one or more non-albicans 
Candida species or to C. albicans were selected. The data collected included patient characteristics on ICU admission 
and at the onset of candidemia.
Results: Among the 136 patients analyzed, 78 (57.4%) had candidemia caused by C. albicans. These patients had earlier 
onset of infection (11.1 ± 14.2 days after ICU admission vs. 17.4 ± 17.7, p = 0.02), higher severity scores on ICU admission 
(SOFA: 10.4 ± 4.7 vs. 8.6 ± 4.6, p = 0.03; SAPS II: 57.4 ± 22.8 vs. 48.7 ± 15.5, P = 0.015), and were less often neutropenic 
(2.6% vs. 12%, p = 0.04) than patients with candidemia due to non-albicans Candida species.
Conclusions: Although patients infected with Candida albicans differed from patients infected with non-albicans 
Candida species for a few characteristics, no clinical factor appeared pertinent enough to guide the choice of empirical 
antifungal therapy in ICU.
Introduction
The importance of fungal infections in Intensive Care
Units (ICUs) was recently underlined by the EPIC Study
II, since fungal agents represented 19% of positive isolates
[1]. Moreover, candidemia still raises numerous thera-
peutic issues to Intensive Care physicians. The relation-
ship between prognosis and early initiation of the
adequate antifungal therapy is well established [2-4]. Ide-
ally, adequate therapy must be started much before can-
didemia is ascertained, therefore much before the
causative Candida species is identified and its suscepti-
bility to antifungals is known. Broad spectrum antifun-
gals have enriched the therapeutic arsenal in the past few
years. The above therapeutic constraints might tempt cli-
nicians to use these agents widely. However, apart from
financial aspects, an excessive usage could become dele-
terious by resulting in the selection of strains with
reduced susceptibility.
In a prospective multicenter observational study named
AmarCand performed to assess the current epidemiol-
ogy, management and prognosis of invasive Candida
infections in French ICUs, we demonstrated that 95.6% of
C. albicans strains were susceptible to fluconazole
whereas only 68% of non-albicans Candida were suscep-
tible [5]. Thus, among data that could guide the choice of
initial therapy, the availability of elements that would
allow a binary distinction, with sufficient liability,
between albicans or non-albicans Candida could repre-
sent an interesting first step.
In the present paper, the characteristics of patients
from the AmarCand study, on ICU admission and at the
onset of candidemia, are described according to whether
candidemia was due to an albicans  or a non-albicans
Candida strain.
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Materials and methods
The AmarCand ("Analyse du Management en Anesthésie et 
Réanimation des Candidoses invasives") study
This study has already been described in two publications
from the Group [5,6]. Briefly, AmarCand was a prospec-
tive, multicentre, national and observational study. Adult
ICU patients with invasive Candida infection requiring a
systemic antifungal therapy were included. Criteria used
for diagnosis were those proposed in 2002 by the mem-
bers of the European Organization for Research and
Treatment of Cancer/Invasive Fungal Infections Cooper-
ative Group and the National Institute of Allergy and
Infectious Diseases Mycoses Study Group [7]. In accor-
dance with the French law, approval of an Ethics Com-
mittee was not required. However, all patients gave
informed consent to participate. Approval of the "Com-
mission Nationale de l'Informatique et des Libertés" was
obtained, ensuring that patient data were kept confiden-
tial according to the French regulation.
For each episode of invasive Candida infection, demo-
graphic characteristics, underlying diseases, current hos-
pitalization, severity of illness, and process of care were
recorded by each investigator on a standardized report
form. Identification of the Candida  isolates was per-
formed in mycology and microbiology laboratories using
the routine methods of each hospital. Isolates were classi-
fied as susceptible (S), susceptible-dose dependent (S-
DD), or resistant (R) to antifungals according to CLSI
interpretive categories [8].
Comparison of candidemia due to Candida albicans vs. non-
albicans Candida species
F o r  t h i s  c o m p a r i s o n ,  w e  i d e n t i f i e d  p a t i e n t s  f r o m  t h e
AmarCand study with a candidemia acquired in ICU and
exclusively due either to C. albicans or to one or more
non-albicans Candida species. These groups were com-
pared for the patients' characteristics on ICU admission
and at the onset of candidemia.
Statistics
Data were analyzed using SAS® 8.2 (SAS Institute Inc.,
Cary, NC, USA). Variables were expressed as mean values
± standard deviation for numerical variables and as fre-
quencies and percentages for categorical variables.
Groups were compared using the Chi-square and Fisher's
exact tests. Continuous variables were compared using
the Student's t test. Statistical significance was accepted
at the 5% level.
Results
A total of 271 evaluable patients were included in the
AmarCand study between October 2005 and May 2006.
A total of 101 ICUs participated: 44 (43.6%) medico-sur-
gical ICUs, 28 (27.7%) medical ICUs and 29 (28.7%) sur-
gical ICUs.
For the purposes of the present paper, we excluded
from the 271 evaluable patients: 87 patients with invasive
candidiasis but no candidemia, 13 patients with mixed
candidemia due to albicans  and non-albicans Candida
species, and 35 patients who acquired candidemia before
admission in ICU. Therefore, 136 patients were included
in the present analysis.
Candidemia was due to C. albicans in 78 (57.4%)
patients. It was due to non-albicans Candida species in
58 (42.6%) patients. In total, 63 non-albicans Candida
isolates were identified: C. glabrata n = 25, C. parapsilosis
n = 12, C. tropicalis n = 9, C. kefyr n = 4, C. krusei n = 6
and other species n = 7. In vitro susceptibility to flucon-
azole was determined for 112 isolates. The rate of flucon-
azole-R or S-DD Candida was 3.3% (2/61) for C. albicans,
50.0% (10/20) for C. glabrata, 18.2% (2/11) for C. parapsi-
losis, 100% (3/3) for C. krusei, 25% (2/8) for C. tropicalis,
0% (0/4) for C. kefyr, and 40% (2/5) for the remaining
Candida species. Susceptibility to fluconazole was deter-
mined for 61 episodes of candidemia due to C. albicans
and for 47 episodes due to non-albicans Candida species.
The rate of episodes due to a fluconazole-R or S-DD Can-
dida was 3.3% and 38.3%, respectively (P < 0.0001).
Table 1 provides the major characteristics of patients
on admission in ICU. The only significant differences
observed between both types of candidemia were the
Simplified Acute Physiology Score II (SAPS II) and the
Sepsis-related Organ Failure Assessment (SOFA) score,
which were significantly higher in case of infection with
C. albicans.
The time from ICU admission to onset of candidemia
was 13.8 ± 16.1 days. It was significantly shorter in the
case of candidemia due to C. albicans: 11.1 ± 14.2 days vs.
17.4 ± 17.7 days with non-albicans Candida species (P =
0.02). Candidemia developed within six days after admis-
sion in ICU for 59 patients. Such an early infection was
significantly more frequent when candidemia was due to
C. albicans than when it was due to non-albicans Can-
dida  species (40/78 vs. 19/58, P = 0.03). Neutropenia
(absolute neutrophil count <500 cells/mm3) was concom-
itant to candidemia in nine patients. It was significantly
more frequent when candidemia was caused by non-albi-
cans Candida species than when it was caused by C. albi-
cans (7/58 vs. 2/78, P = 0.04).
The main features of the patients' care at the onset of
candidemia are shown in Table 2. There were no signifi-
cant differences between the two patient groups, notably
for previous exposure to azole agents.
Discussion
In this study, the characteristics of patients with candi-
demia caused by non-albicans Candida species versusLeroy et al. Critical Care 2010, 14:R98
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Candida albicans in ICU were compared. The main
result is that only a few significant differences were
observed: severity of the disease, the time to candidemia
onset and the rate of underlying neutropenia. So, we did
not identify a parameter pertinent enough to allow a
binary distinction between albicans  or non-albicans
Candida and to guide the choice of empirical antifungal
therapy.
Studies that compare the epidemiological characteris-
tics of patients with candidemia caused by non-albicans
Candida species versus Candida albicans are scarce and
their results are disparate.
Three studies included patients who were not all adults
and/or not all admitted in ICU. Cheng et al. retrospec-
tively analyzed 130 cases of fatal candidemia due to either
a C. albicans (n = 68) or a non-albicans C. species (n = 62)
[9]. Multivariate analyses showed that factors indepen-
dently associated with C. albicans infection were the age
≥65 years, hyperleukocytosis (>15,000 cells/mm3), and
immunosuppressant therapy. Shorr et al. retrospectively
analyzed the files of 245 candidemic patients from two
different hospitals [10]. C. albicans represented 52% of
the causative species. None of the parameters describing
severity of the disease and previous exposition to azole
agents was significantly predictive of a candidemia due to
a non-albicans Candida strain. The third report arises
from a large registry of 2,019 patients included between
July 2004 and March 2008 in 23 North American hospi-
tals [11]. Underlying hematological malignancy and bone
m a r r o w  g r a f t i n g  w e r e  l e s s  c o m m o n  i n  p a t i e n t s  w i t h  a
candidemia due to C. albicans. Prior antifungal therapy
was reported in 43% of the 2,019 patients. It was signifi-
cantly less frequent in patients with C. albicans infection
(38.8% vs. 46.5%, P < 0.001).
Three other studies were performed exclusively in ICU.
In Australia Playford et al. carried out a three-year pro-
spective, national survey [12]. A total of 179 episodes of
candidemia were studied, of which 62% were related to C.
albicans. Factors associated independently with a candi-
demia not related to C. albicans were recent intra-
abdominal surgery and recent exposition to systemic
antifungal therapy. Chow et al. compared 79 patients
Table 1: Clinical characteristics of patients on admission to intensive care unit
Total
N = 136
Candidemia due to C. albicans
N = 78
Candidemia due to non-albicans
Candida species
N = 58
P value
Age (years) 62.1 ± 14.9 61.0 ± 17.2 63.5 ± 11.1 0.32
Male gender 84 (61.8) 45 (57.7) 39 (67.2) 0.26
SAPS II 53.8 ± 20.4 57.4 ± 22.8 48.7 ± 15.5 0.015
SOFA 9.6 ± 4.7 10.4 ± 4.7 8.6 ± 4.6 0.03
Underlying disease* 0.35
Absent or nonfatal 63 (46.3) 37 (47.4) 26 (44.8)
Ultimately fatal 58 (42.7) 35 (44.9) 23 (39.7)
Rapidly fatal 15 (11.0) 6 (7.7) 9 (15.5)
Chronic renal failure 26 (19.1) 16 (20.5) 10 (17.2) 0.63
Type 1 diabetes mellitus 16 (11.8) 8 (10.3) 8 (13.8) 0.52
Solid neoplastic tumor 32 (23.5) 19 (24.4) 13 (22.4) 0.79
Hematological malignancy 7 (5.1) 4 (5.1) 3 (5.2) 0.99
Immunosuppression 28 (20.6) 15 (19.2) 13 (22.4) 0.65
Corticotherapy 10 (7.4) 3 (3.8) 7 (12.1) 0.06
HIV infection 2 (1.5) 2 (2.6) 0 0.17
Cancer chemotherapy 10 (7.4) 5 (6.4) 5 (8.6) 0.78
Organ transplantation 5 (3.7) 2 (2.6) 3 (5.2) 0.50
Immunosuppressant therapy 4 (2.9) 2 (2.6) 2 (3.4) 0.88
Intravenous drug use 2 (1.5) 1 (1.3) 1 (1.7) 0.83
Neutropenia (<500/mm3) 9 (6.6) 2 (2.6) 7 (12.1) 0.04
Results are expressed as mean ± SD values or numbers (%) of patients.
HIV: human immunodeficiency virus; SAPS: simplified acute physiology score; SOFA: sepsis-related organ failure assessment
*Classified according to the criteria proposed by McCabe and Jackson [17]Leroy et al. Critical Care 2010, 14:R98
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with candidemia due to C. albicans and 67 patients with
candidemia due to non-albicans Candida species [13].
Previous exposition to azole agents, duration of central
venous catheter implantation and the number of antimi-
crobial agents per day were associated with non-albicans
Candida infection in multivariate analyses. Conversely,
the duration of parenteral nutrition was associated with a
reduced risk of non-albicans Candida infection. Finally,
189 candidemic patients (C. albicans: 56%) were included
in the international, multicenter, retrospective study of
Holley et al. [14]. Factors associated independently with
candidemia due to non-albicans Candida species were
female gender and duration of central venous catheter
implantation using multivariate analysis.
Our results obtained in 136 episodes of candidemia
contrast with those of the three above studies performed
in ICU [12-14]. Indeed, neither intra-abdominal surgery,
previous exposure to azole agents, duration of central
venous catheter implantation, nor female gender were
associated with non-albicans Candida infection. Our
results are however in line with those of Shorr et al., who
could not identify clearly any parameter associated with
the Candida species causative of candidemia [10].
Several consensual recommendations for the manage-
ment of invasive Candida infections have been published
in the last few years. In the French recommendations,
which go back to 2004, the algorithm takes into account
previous exposition to azole agents [15]. Empirical treat-
ment based on fluconazole is proposed for patients who
had not been exposed previously to azole agents. The
2009 North American recommendations propose empiri-
cal broad-spectrum treatment with an echinocandin for
all ICU patients irrespective of previous exposition to
azole agents [16]. Both recommendations propose to
continue therapy with de-escalation if the causative strain
is susceptible to fluconazole. Our results showing a high
incidence (38.3%) of fluconazole non-susceptible Can-
dida, and no pertinent parameter able to predict the spe-
cies of causative Candida  suggest that, in France and
probably the rest of Europe, the use of the North Ameri-
can recommendation may now be more adequate. The
use of echinocandin as first-line treatment (before the
identification of the causative Candida strain and deter-
mination of its susceptibility) for all ICU patients suffer-
ing from candidemia could decrease the incidence of
inappropriate empirical antifungal therapy and thus
improve outcome of patients with such invasive candidia-
sis [3]. A de-escalation could be proposed in patients who
are clinically stable when minimum inhibitory concentra-
tion (MIC) to fluconazole is ≤8 mg/L [16].
Conclusions
Comparison of the characteristics of ICU patients with
candidemia caused by non-albicans Candida species ver-
sus  Candida albicans did not allow identifying any
parameter pertinent enough to guide the choice of empir-
ical antifungal therapy.
Table 2: Main features of patients' care at the onset of candidemia
Total
N = 136
Candidemia due to
C.albicans
N = 78
Candidemia due to non-albicans
Candida species
N = 58
P value
Recent surgery (<3 months) 75 (55.1) 43 (55.1) 32 (55.2) 0.99
Intra-abdominal 56 (41.2) 32 (41.0) 24 (41.6) 0.95
Vascular 9 (6.6) 6 (7.7) 3 (5.2) 0.54
Time from surgery to candidemia (days) 23.6 ± 20.7 22.6 ± 19.3 25.0 ± 22.7 0.62
Invasive mechanical ventilation 106 (77.9) 62 (79.5) 44 (75.9) 0.61
CVC 122 (89.8) 68 (87.2) 54 (93.2) 0.26
Time from CVC placement to candidemia (days) 15.2 ± 16.9 13.1 ± 14.9 17.8 ± 18.9 0.13
UC 122 (89.8) 68 (87.2) 54 (63.2) 0.26
Time from UC placement to candidemia (days) 16.4 ± 17.0 14.7 ± 16.7 18.6 ± 17.4 0.22
Prior antibiotherapy 84 (61.8) 48 (61.5) 36 (62.1) 0.95
Duration of antibiotherapy before candidemia 
(days)
18.2 ± 13.5 17.8 ± 14.4 18.7 ± 12.4 0.77
Previous exposure to azole agents 23 (16.9) 11 (14.1) 12 (20.7) 0.31
Vasoactive drug use 31 (22.8) 20 (25.6) 11 (19.0) 0.36
Results are expressed as mean ± SD values or numbers (%) of patients. CVC: central venous catheter; UC: urinary catheterLeroy et al. Critical Care 2010, 14:R98
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Key messages
• Characteristics of patients with candidemia caused
by non-albicans Candida species versus Candida
albicans are quite similar at the onset of candidemia.
• Empiric antifungal therapy should be based on a
broad-spectrum treatment effective against non-albi-
cans Candida species and Candida albicans.
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